|
WO2021025899A1
|
|
Phosphorodiamidate morpholino oligomer pharmaceutical compositions
|
|
WO2020257489A1
|
|
Methods for treating muscular dystrophy
|
|
WO2020214763A1
|
|
Compositions for treating muscular dystrophy
|
|
WO2020198268A1
|
|
Methods for treating muscular dystrophy with casimersen
|
|
US2020190516A1
|
|
Exon skipping oligomer conjugates for muscular dystropy
|
|
WO2020028254A1
|
|
Trimeric peptides for antisense delivery
|
|
TW202020153A
|
|
Exon skipping oligomers for muscular dystrophy
|
|
EP3810150A2
|
|
Exon skipping oligomers and oligomer conjugates for muscular dystrophy
|
|
WO2019241385A2
|
|
Exon skipping oligomers for muscular dystropy
|
|
EP3806868A2
|
|
Exon skipping oligomers for muscular dystrophy
|
|
WO2019209764A2
|
|
Exon skipping oligomers and oligomer conjugates for muscular dystrophy
|
|
TW202002990A
|
|
Chimeric peptides for antisense delivery
|
|
WO2019079637A2
|
|
Antisense oligomer compounds
|
|
WO2019079386A1
|
|
Cell-penetrating peptides for antisense delivery
|
|
WO2019079367A1
|
|
Bicyclic peptide oligonucleotide conjugates
|
|
WO2019067979A1
|
|
Combination therapies for treating muscular dystrophy
|
|
EP3687547A1
|
|
Combination therapies for treating muscular dystrophy
|
|
EP3687577A1
|
|
Combination therapies for treating muscular dystrophy
|
|
WO2019060862A1
|
|
Processes for preparing phosphorodiamidate morpholino oligomers via fast-flow synthesis
|
|
KR20200046069A
|
|
How to treat muscular dystrophy
|
